Treatment of early and refractory dermatomyositis with infliximab: a report of two cases

The idiopathic inflammatory myopathies embody the largest group of acquired and potentially treatable causes of skeletal muscle weakness. The three major groups of this disorder are polymyositis (PM), dermatomyositis (DM), and inclusion body myositis. Corticosteroids continue to be the mainstay of i...

Full description

Saved in:
Bibliographic Details
Published in:Clinical rheumatology 2007-07, Vol.26 (7), p.1186-1188
Main Authors: Dold, Sylvia, Justiniano, Maria E, Marquez, Javier, Espinoza, Luis R
Format: Article
Language:English
Subjects:
Adult
Antibodies, Monoclonal - therapeutic use
Corticosteroids
Dermatologic Agents - therapeutic use
Dermatomyositis
Dermatomyositis - drug therapy
Dermatomyositis - pathology
Drug Resistance
Drug Therapy, Combination
Female
Glucocorticoids - therapeutic use
Humans
Hydroxychloroquine - therapeutic use
Inflammation
Infliximab
Medical research
Methylprednisolone - therapeutic use
Monoclonal antibodies
Muscular system
Myositis
Polymyositis
Prednisone - therapeutic use
Skeletal muscle
Treatment Outcome
Tumor necrosis factor-α
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The idiopathic inflammatory myopathies embody the largest group of acquired and potentially treatable causes of skeletal muscle weakness. The three major groups of this disorder are polymyositis (PM), dermatomyositis (DM), and inclusion body myositis. Corticosteroids continue to be the mainstay of initial treatment in the majority of cases of PM/DM. The treatment of refractory disease can be challenging despite the utilization of the medications currently available. We report two patients with refractory DM who were treated with infliximab. We describe their presentation, clinical course, treatment, and outcomes.
ISSN:0770-3198
1434-9949
DOI:10.1007/s10067-006-0325-z